BioSove is a research institute focused on a single question:
> Why do breakthrough biological treatments remain inaccessible to most patients who need them?
We don't work in laboratories. We work in the space between the laboratory and the patient — studying the regulatory, economic, logistical, and social barriers that determine whether a scientific breakthrough becomes an available treatment or stays locked in a journal.
Our Belief
The next great leap in medicine won't come from discovering new cures. It will come from delivering the cures we already have.
Methodology
We combine health economics research, regulatory analysis, and systems thinking to map the barriers between breakthrough and patient. Our work is grounded in data, anchored to specific costs and timelines, and written for both experts and the informed public.
Active Research
The Anatomy of Treatment Cost
Status: In Progress
A gene therapy can cure a child's blindness. It costs $850,000 per eye. This project dissects the cost structure of biological treatments — from R&D amortization to manufacturing complexity to pricing strategy — to identify where structural intervention could bring costs down without killing innovation.
Deliverables:
- Cost breakdown analysis of 10 landmark biological treatments
- Comparison of pricing models across US, EU, and emerging markets
- Policy brief on cost-reduction levers available to regulators
- What fraction of total development time is regulatory vs. scientific vs. manufacturing?
- Which stages have seen the least efficiency improvement over the past 20 years?
- What can be learned from fields with faster development cycles (software, materials science)?
First research note published: "The Accessibility Crisis in Biological Medicine"
Pipeline Bottleneck Analysis
Status: Scoping
It takes 10–15 years and $2 billion to bring a drug from lab to patient. Where exactly is the bottleneck? This project maps the drug development pipeline stage by stage, measuring time and cost at each gate, to identify where compression is feasible.
Research questions:
Orphan Drug Economics
Status: Early Research
Rare diseases collectively affect over 300 million people worldwide. But each individual condition is "too rare" to justify standard pharmaceutical investment. This project analyzes alternative economic models — subscription pricing, international risk pooling, AI-accelerated trial design — that could make rare disease treatment financially viable.
Precision Medicine at Scale
Status: Scoping
Precision medicine promises treatments tailored to your genome. But hospitals, insurers, and supply chains were built for standardized care. This project studies the systemic adaptations — in logistics, data infrastructure, reimbursement models, and clinical workflows — needed to deliver personalized medicine beyond research hospitals.
Founding Note: The Accessibility Crisis in Biological Medicine
Published March 2026
The Gap
In 2023, the FDA approved Casgevy — the first CRISPR-based gene therapy. It can cure sickle cell disease, a condition that causes excruciating pain crises and shortens lives by decades. The price: $2.2 million per patient.
Sickle cell disease affects approximately 100,000 people in the United States alone, and millions worldwide — predominantly in Sub-Saharan Africa, where healthcare spending per capita averages $83 per year.
The cure exists. The access doesn't.
This is not an isolated case. It is the defining pattern of modern biological medicine:
- Luxturna (gene therapy for inherited blindness): $850,000 per eye
- Zolgensma (gene therapy for spinal muscular atrophy): $2.1 million per dose
- CAR-T cell therapies for certain cancers: $400,000–$500,000 per treatment
- Average orphan drug annual cost: $32,000 per patient (vs. $2,115 for non-orphan drugs)
Why This Matters Now
Three trends are converging to make this crisis both worse and more urgent:
1. The pipeline is accelerating. Gene therapies, cell therapies, RNA medicines, and CRISPR applications are moving from experimental to approved at unprecedented speed. The FDA's gene therapy pipeline alone has over 1,000 active INDs. Each approval will add another treatment that works but costs too much.
2. The diseases are getting rarer. As we move from common conditions to rare genetic diseases, each patient population shrinks. Pharma's unit economics — which depend on large patient pools to amortize R&D costs — break down. The patients who need these treatments most are the least commercially attractive.
3. Healthcare systems weren't built for this. Insurance models, hospital formularies, and national drug pricing frameworks were designed for mass-market pharmaceuticals — pills manufactured at scale for millions. They have no mechanism for a one-time, patient-specific genetic intervention that costs seven figures.
What BioSove Will Study
We've identified four problem clusters that collectively explain why the gap persists:
Treatment Economics — The cost structure of biological treatments is fundamentally different from traditional pharmaceuticals. A pill has near-zero marginal cost after R&D; a gene therapy is manufactured individually for each patient. We need to understand these cost structures in detail before we can propose alternatives.
Pipeline Compression — The 10–15 year development timeline for new treatments is not a law of nature. It's the result of specific regulatory, logistical, and institutional choices — some necessary, some legacy. We study where time is being wasted and what models could safely compress it.
Orphan Drug Viability — 7,000+ known rare diseases, treatments for fewer than 5% of them. The standard pharma business case fails when patient populations are measured in thousands, not millions. We analyze alternative models: platform trials that share infrastructure across diseases, gene therapy vectors that can be reprogrammed for different targets, and insurance models designed for high-cost one-time treatments.
System Adaptation — Precision medicine is personal by definition. But healthcare delivery is industrial by design. We study the structural adaptations needed — from hospital infrastructure to insurance frameworks to supply chain logistics — to deliver personalized biological treatments at scale.
Our Approach
BioSove is not a laboratory. We don't discover treatments. We study why existing treatments don't reach patients, and we publish our findings openly.
We believe that the accessibility crisis in biological medicine is not primarily a scientific problem — it is an economic, regulatory, and systemic one. And systemic problems require systemic research.
This is our first publication. More will follow.
Why Gene Therapy Costs What It Costs
Research Note — March 2026
The $850,000 Question
Luxturna, a gene therapy for inherited retinal dystrophy, is priced at $850,000 per eye. Zolgensma, for spinal muscular atrophy, costs $2.1 million per treatment. Hemgenix, for hemophilia B, was launched at $3.5 million — the most expensive drug in history.
These are not arbitrary numbers. They emerge from a cost structure fundamentally different from traditional pharmaceuticals. Understanding that structure is the first step toward changing it.
The Cost Anatomy
1. R&D Amortization Over Tiny Populations
Traditional drugs spread R&D costs across millions of patients. A gene therapy for a rare disease might treat 500 patients per year worldwide. The same $1 billion development cost, divided by 500 instead of 5 million, produces a per-patient cost three orders of magnitude higher.
This is arithmetic, not greed. But it's arithmetic that current healthcare systems weren't designed to handle.
2. Manufacturing Complexity
Small-molecule drugs are manufactured through chemical synthesis — scalable, standardized, and well-understood. Gene therapies require biological manufacturing: growing viral vectors in cell cultures, purifying them to pharmaceutical grade, and maintaining sterility throughout. Each batch is a biological process with inherent variability.
Current manufacturing yields are low. A single batch of AAV vector (the most common gene therapy delivery vehicle) might produce enough material for 100-200 patients. Scaling up isn't a matter of building a bigger reactor — it requires fundamentally different bioprocessing approaches.
3. The Single-Dose Problem
Gene therapy is designed to be curative — one treatment, permanent effect. But healthcare payment systems are built for chronic treatment. Insurers would rather pay $50,000 per year for 20 years than $1 million once, even though the total is the same. This mismatch between cure economics and payment infrastructure inflates perceived cost.
Where the Leverage Points Are
Manufacturing innovation: Next-generation viral vector production (suspension culture, synthetic biology-designed capsids) could reduce manufacturing costs by 5-10x within a decade.
Payment model reform: Outcomes-based contracts (pay only if the therapy works), installment plans, and international risk pools could address the single-dose payment problem without reducing the drug's price.
Platform economics: As gene therapy technology matures, platform approaches (same vector, different gene payloads) could amortize manufacturing infrastructure across multiple therapies, reducing per-therapy development costs.
Regulatory harmonization: A gene therapy approved in the US must go through largely separate approval processes in the EU, Japan, and other markets. Mutual recognition agreements could reduce duplicative regulatory costs.
What We Don't Know Yet
- What is the minimum viable manufacturing scale for gene therapy to reach price parity with 10-year chronic treatment courses?
- Can AI-driven process optimization reduce batch failure rates to pharmaceutical-grade consistency?
- How do different payment models affect patient access in practice (not just in theory)?
This research note is part of BioSove's ongoing analysis of treatment accessibility barriers.
Reach Out
BioSove is in its early research stage. We are building a foundation of analysis before seeking formal partnerships — but we want to hear from you.
For Researchers If you work on health economics, regulatory science, or treatment accessibility, we're particularly interested in:
- Cost structure data for biological treatments
- Comparative regulatory analysis across jurisdictions
- Alternative economic models for rare disease treatment
For Patients and Advocates We write for you. If you have a story about treatment access barriers, it matters to our research.
Use the contact form below. We read every message.